Ayurvedic management of female infertility

Phase 3

Not yet recruiting

• Conditions: Female infertility associated withanovulation. Ayurveda Condition: VANDHYA,

• Registration Number: CTRI/2022/03/040864
• Lead Sponsor: Director ITRA Jamnagar

Brief Summary

This is an open labelled single armclinical trial to study the efficacy of Lashunadi taila matrabasti along withSatapushpa choorna orally in the management of female infertility with specialreference to anovulation factor in sthoulya. 20 Diagnosed female infertilepatients with overweight (BMI >25 kg/m2) or obesity (BMI > 30 kg/m2)  between age group of 20 year – 40 year basedUSG parameters (anovulatory cycle), fulfilling the selection criteria will beselected & given Matrabasti of Lashunadi Taila  for 2months (2 consecutive menstrual cycle,after the cessation of menses daily for 7days) along with Shatapushpa Choornaorally for 2 months. Shatapushpa Choorna will be given orally 5gm in emptystomach (Morning & evening with Goghrita).Lashunadi Taila Matrabasti willbe given through rectal route (60ml) at morning 8:30 to 10:30 after light diet.The follow up period will be one month.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-04
• Last Update Posted: 2022-02-25

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

• Female Patients of reproductive age ≥ 20 and ≤40 years Patients having overweight (BMI 25-29 Kg/M2 ) or obese (BMI >30 Kg/M2) Patients who have completed active married life of minimum1-year duration and suffering from Infertility with 2 or more consecutive anovulatory cycles.
• Both Primary and secondary infertile patients having anovulatory cycle or with immature ovarian follicle.
• Patient eligible& willing for Basti Patients willing to participate in trial.

Exclusion Criteria

• Female Patients having age < 20years and >40years.
• Patient with infectious diseases of reproductive tract like tuberculosis, sexually transmitted diseases Organic lesions of reproductive tract like tuberculosis, carcinoma and congenital deformities.
• Patients with history of cardiac diseases, Uncontrolled Diabetes (above 200 mg/dl- RBS) & Hypertension (Systolic BP above 160 & Diastolic above 100mmhg), TB, etc.
• Patient with Hepatitis C, Hepatitis B Patient not eligible for Basti Pitta dominant Prakruti patients.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected that the trial drugs will induce the ovulation.	3 months

Secondary Outcome Measures

Name	Time	Method
Trail drugs will cure menstrual abnormalities associated with anovulation like irregular, scanty menstruation, dysmenorrhoea	It is expected that drugs will help to reduce BMI of patient.

Trial Locations

Locations (1)

ITRA Jamnagar; 🇮🇳 Jamnagar, GUJARAT, India

ITRA Jamnagar

🇮🇳Jamnagar, GUJARAT, India

Aswani GS

Principal investigator

9605932933

aswanigv@gmail.com